肺癌生物样本采集及研究

注册号:

Registration number:

ChiCTR-COC-16008247 

最近更新日期:

Date of Last Refreshed on:

2016-04-08 07:43:02 

注册时间:

Date of Registration:

2016-04-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肺癌生物样本采集及研究

Public title:

Collection and study of biological samples of lung cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肺癌生物样本采集及研究

Scientific title:

Collection and study of biological samples of lung cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐玉芬 

研究负责人:

徐玉芬 

Applicant:

Xu Yu-fen 

Study leader:

Xu Yu-fen 

申请注册联系人电话:

Applicant telephone:

+86 18268399773

研究负责人电话:

Study leader's
telephone:

+86 18268399773

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

135880607@163.com

研究负责人电子邮件:

Study leader's E-mail:

135880607@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省嘉兴市中环南路1882号

研究负责人通讯地址:

浙江省嘉兴市中环南路1882号

Applicant address:

1882 Central South Road, Jiaxing, Zhejiang, China

Study leader's address:

1882 Central South Road, Jiaxing, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

Jiaxing First Hospital

研究负责人所在单位:

嘉兴市第一医院

Affiliation of the Leader:

Jiaxing First Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-0006

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴第一医院医学伦理委员会

Name of the ethic committee:

Jiaxing first Hospital Medical Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2016-03-07 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

Jiaxing First Hospital

研究实施负责(组长)单位地址:

浙江省嘉兴市中环南路1882号

Primary sponsor's address:

1882 Central South Road, Jiaxing, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴市

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院

具体地址:

浙江省嘉兴市中环南路1882号

Institution
hospital:

Jiaxing First Hospital

Address:

1882 Central South Road, Jiaxing, Zhejiang, China

经费或物资来源:

嘉兴市重点科技创新团队;嘉兴市重点学科(呼吸科、心胸外科)、扶持学科(肿瘤内科)

Source(s) of funding:

Jiaxing key science and technology innovation team;Key subjects of Jiaxing (Department of respiration, thoracic surgery), supportive subjects (Department of internal medicine)

研究疾病:

肺癌  

Target disease:

Lung Cancer

研究疾病代码:

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

为临床进行肿瘤分期、疗效评估、预后等研究提供支持,为基础研究提供实验材料。  

Objectives of Study:

To provide support for clinical research on staging, evaluation and prognosis of tumor, and to provide experimental materials for basic research.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

不符合纳入标准或临床资料不全的患者

Exclusion criteria:

the patients who did not accord with the standard or clinical data were not complete

研究实施时间:

Study execute time:

From 2016-05-01 00:00:00 To 2021-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-05-01 00:00:00 To 2021-12-31 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

200

Group:

1

Sample size:

干预措施:

癌组织

干预措施代码:

Intervention:

Cancer tissue

Intervention code:

组别:

2

样本量:

200

Group:

2

Sample size:

干预措施:

癌旁组织

干预措施代码:

Intervention:

Carcinoma adjacent tissue

Intervention code:

组别:

3

样本量:

200

Group:

3

Sample size:

干预措施:

正常组织

干预措施代码:

Intervention:

Normal tissue

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

嘉兴 

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院 

单位级别:

三级甲等 

Institution
hospital:

Jiaxing First Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

血清蛋白质

指标类型:

主要指标

Outcome:

serum proteome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

组织蛋白

指标类型:

主要指标

Outcome:

Tissue protein

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

肺癌组织

组织:

Sample Name:

Lung cancer tissue

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

癌旁组织

组织:

Sample Name:

adjacent tissue

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

正常组织

组织:

Sample Name:

normal tissue

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后;我院内网查询

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The end of the study;Query in our hospital intranet

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

自建数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Self built database

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-04-08 07:43:02